Logo Image
|Articles|February 12, 2015

Biotec Services International Completes its Rebrand into PCI

PCI is pleased to announce that further to the acquisition in September 2014 of Biotec Services International, the company has rebranded as part of the PCI group.

PCI is pleased to announce that further to the acquisition in September 2014 of Biotec Services International, the company has rebranded as part of the PCI group. This rebrand expands PCI’s capability to deliver an integrated pharmaceutical service for global studies of investigational medicinal products and include manufacturing, packaging and labeling, QP and GMP consultancy, global distribution and returned drug management, as well as consultant services.

 

Read the full release here.

Related to this article

View more
The Human Side of Clinical Trials: How Measuring Readiness at Training Predicts Trial Risk Before It Shows Up in the Data
The Human Side of Clinical Trials: How Measuring Readiness at Training Predicts Trial Risk Before It Shows Up in the Data
This episode of The Human Side of Clinical Trials, hosted by Brian S. McGowan, PhD, FACEHP, chief learning officer and co-founder of ArcheMedX, Inc., and Kelly Ritch, chief operating officer of ArcheMedX, Inc., explores why training completion metrics like attendance and quiz scores fail to capture true study readiness, and how measuring both competence and confidence can reveal trial risks before enrollment even begins.
Read more
What the Epilepsy Community Has Taught Us About Trial Feasibility
What the Epilepsy Community Has Taught Us About Trial Feasibility
In this video interview, Amélie Lothe, global medical community head for rare epilepsies at UCB Pharma, shares what she has learned firsthand from families living with Dravet syndrome and CDKL5 deficiency disorder about what makes trial participation possible—and what makes it not.
Read more